BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

331 related articles for article (PubMed ID: 23831164)

  • 21. Cost-effectiveness analysis: cardiovascular benefits of proton pump inhibitor co-therapy in patients using aspirin for secondary prevention.
    Saini SD; Fendrick AM; Scheiman JM
    Aliment Pharmacol Ther; 2011 Jul; 34(2):243-51. PubMed ID: 21615437
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Low-dose aspirin and upper gastrointestinal bleeding in primary versus secondary cardiovascular prevention: a population-based, nested case-control study.
    Lin KJ; De Caterina R; García Rodríguez LA
    Circ Cardiovasc Qual Outcomes; 2014 Jan; 7(1):70-7. PubMed ID: 24254886
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Underutilization of gastroprotective strategies in aspirin users at increased risk of upper gastrointestinal complications.
    Targownik LE; Metge CJ; Leung S
    Aliment Pharmacol Ther; 2008 Jul; 28(1):88-96. PubMed ID: 18410563
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cardioprotective effects and gastrointestinal risks of aspirin: maintaining the delicate balance.
    Kimmey MB
    Am J Med; 2004 Sep; 117 Suppl 5A():72S-78S. PubMed ID: 15478856
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost-effectiveness of proton pump inhibitor cotherapy in patients taking long-term, low-dose aspirin for secondary cardiovascular prevention.
    Saini SD; Schoenfeld P; Fendrick AM; Scheiman J
    Arch Intern Med; 2008 Aug; 168(15):1684-90; discussion 1691. PubMed ID: 18695083
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of low-dose proton pump inhibitor on preventing upper gastrointestinal bleeding in chronic kidney disease patients receiving aspirin.
    Lim H; Kim JH; Baik GH; Park JW; Kang HS; Moon SH; Park CK
    J Gastroenterol Hepatol; 2015 Mar; 30(3):478-84. PubMed ID: 25252119
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Aspirin and proton pump inhibitor combination therapy for prevention of cardiovascular disease and Barrett's esophagus.
    Peura DA; Wilcox CM
    Postgrad Med; 2014 Jan; 126(1):87-96. PubMed ID: 24393755
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of Aspirin Prescribing and Gastrointestinal Bleeding in Adults 60 Years of Age and Older in a Large, Academic Health System.
    Potthast KL; Billups SJ; Fixen DR; Titus O; Saseen JJ; Linnebur SA
    Sr Care Pharm; 2024 Jun; 39(6):218-227. PubMed ID: 38803024
    [No Abstract]   [Full Text] [Related]  

  • 29. Lower GI bleeding is more common than upper among patients on dual antiplatelet therapy: long-term follow-up of a cohort of patients commonly using PPI co-therapy.
    Casado Arroyo R; Polo-Tomas M; Roncalés MP; Scheiman J; Lanas A
    Heart; 2012 May; 98(9):718-23. PubMed ID: 22523056
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Represcription of low-dose acetylsalicylic acid after discontinuation in patients receiving treatment for secondary cardiovascular disease prevention in the UK.
    Martín-Merino E; Johansson S; Nagy P; García Rodríguez LA
    Am J Cardiovasc Drugs; 2014 Aug; 14(4):319-26. PubMed ID: 25027353
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hospitalizations for upper and lower GI events associated with traditional NSAIDs and acetaminophen among the elderly in Quebec, Canada.
    Rahme E; Barkun A; Nedjar H; Gaugris S; Watson D
    Am J Gastroenterol; 2008 Apr; 103(4):872-82. PubMed ID: 18371130
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Esomeprazole for prevention and resolution of upper gastrointestinal symptoms in patients treated with low-dose acetylsalicylic acid for cardiovascular protection: the OBERON trial.
    Scheiman JM; Herlitz J; Veldhuyzen van Zanten SJ; Lanas A; Agewall S; Nauclér EC; Svedberg LE; Nagy P
    J Cardiovasc Pharmacol; 2013 Mar; 61(3):250-7. PubMed ID: 23188121
    [TBL] [Abstract][Full Text] [Related]  

  • 33. COX-2 inhibitors: complex association with lower risk of hospitalization for gastrointestinal events compared to traditional NSAIDs plus proton pump inhibitors.
    van der Linden MW; Gaugris S; Kuipers EJ; van Herk-Sukel MP; van den Bemt BJ; Sen SS; Herings RM
    Pharmacoepidemiol Drug Saf; 2009 Oct; 18(10):880-90. PubMed ID: 19593747
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Daily low-dose aspirin: beware of GI bleeding.
    Johns Hopkins Med Lett Health After 50; 2012 Mar; 24(1):6. PubMed ID: 22493823
    [No Abstract]   [Full Text] [Related]  

  • 35. Increased risk of stroke after discontinuation of acetylsalicylic acid: a UK primary care study.
    García Rodríguez LA; Cea Soriano L; Hill C; Johansson S
    Neurology; 2011 Feb; 76(8):740-6. PubMed ID: 21270415
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of proton pump inhibitors on clinical outcomes in patients treated with a 6- or 24-month dual-antiplatelet therapy duration: Insights from the PROlonging Dual-antiplatelet treatment after Grading stent-induced Intimal hyperplasia studY trial.
    Gargiulo G; Costa F; Ariotti S; Biscaglia S; Campo G; Esposito G; Leonardi S; Vranckx P; Windecker S; Valgimigli M
    Am Heart J; 2016 Apr; 174():95-102. PubMed ID: 26995375
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prospective cohort study of gastrointestinal complications and vascular diseases in patients taking aspirin: rationale and design of the MAGIC Study.
    Origasa H; Goto S; Shimada K; Uchiyama S; Okada Y; Sugano K; Hiraishi H; Uemura N; Ikeda Y;
    Cardiovasc Drugs Ther; 2011 Dec; 25(6):551-60. PubMed ID: 21842134
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Investigation into the effect of gastric secretion inhibitor for the prevention of upper gastrointestinal lesions associated with low-dose aspirin].
    Nakamura H; Yokoyama H; Yaguchi T; Suzuki Y; Tokuoka K; Watanabe M; Kitagawa Y; Yamada Y
    Yakugaku Zasshi; 2011 Mar; 131(3):445-52. PubMed ID: 21372542
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Risk and prevention of gastrointestinal complications due to low-dose aspirin and other antiplatelet agents].
    Bretagne JF
    Rev Prat; 2008 Sep; 58(13):1434-6, 1439-40. PubMed ID: 18924327
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Burden of upper gastrointestinal symptoms in patients receiving low-dose acetylsalicylic acid for cardiovascular risk management: a prospective observational study.
    Bytzer P; Pratt S; Elkin E; Næsdal J; Sörstadius E
    Am J Cardiovasc Drugs; 2013 Feb; 13(1):27-35. PubMed ID: 23315343
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.